DEF: Aimei Health Seeks Extension for United Hydrogen Merger

Aimei Health Technology Co., Ltd. is seeking shareholder approval to extend its business combination deadline to December 2026 and reduce sponsor extension fees to facilitate its merger with United Hydrogen.

Summary

• Aimei Health is holding an Extraordinary General Meeting on November 26, 2025, to vote on four key proposals.
• The primary proposals are to extend the deadline for completing a business combination from December 6, 2025, to December 6, 2026, and to amend the Investment Management Trust Agreement to reduce the Sponsor's monthly extension fee.
• The current monthly extension fee is $150,000, and the proposed fee is the lesser of $80,000 or $0.033 per outstanding Public Share for each monthly extension.
• Shareholders previously approved a business combination with United Hydrogen Group Inc. on November 6, 2025, but the company anticipates needing more time to close it by early 2026.
• The Board unanimously recommends voting FOR all proposals, including the appointment of MaloneBailey, LLP as the independent auditor for 2025 and an adjournment proposal.
• Public shareholders have redemption rights, allowing them to redeem their shares for approximately $11.33 per share (as of September 26, 2025) if the Article Amendment Proposal is approved.
• The closing price of Aimei Health's shares on the Record Date was $11.32.
• Insiders, including the Sponsor, directors, and officers, hold 1,725,000 Founder Shares and 332,000 Private Units, which would become worthless if a business combination is not completed.

Sentiment

Score: 4

Explanation: The filing indicates a delay in the business combination and a need for an extension, which is generally negative for SPACs. While the reduction in sponsor fees might incentivize the sponsor, it also highlights potential financial strain. The risk of liquidation if proposals are not approved is significant. However, the fact that a target (United Hydrogen) has been identified and approved by shareholders, and the board is actively seeking to extend to complete it, prevents a lower score.

Positives

• The proposed extension of the business combination deadline to December 6, 2026, provides additional time to complete the merger with United Hydrogen, potentially avoiding liquidation.
• The reduction in the Sponsor's monthly extension fee from $150,000 to the lesser of $80,000 or $0.033 per Public Share incentivizes the Sponsor to fund extensions, increasing the likelihood of the merger proceeding.
• Shareholders have already approved the United Hydrogen Business Combination on November 6, 2025, indicating a clear target and a path forward if the extension is granted.
• Public shareholders retain redemption rights if the extension is approved, offering an exit option at approximately $11.33 per share, which is slightly above the closing share price of $11.32 on the Record Date.

Negatives

• The need for an extension indicates delays in closing the United Hydrogen Business Combination, which was approved on November 6, 2025, but is now expected in early 2026, after the current deadline.
• Significant redemptions by public shareholders could reduce the funds in the Trust Account, potentially requiring additional capital for the business combination, which may not be available on acceptable terms or at all.
• The Sponsor, directors, and officers have a conflict of interest, as their Founder Shares and Private Units would be worthless if a business combination is not consummated, incentivizing them to vote for the extension.
• The company explicitly states that without the extension, there is a 'significant risk' of liquidation, which would result in the loss of investment for non-redeeming shareholders.

Risks

• Inability to obtain shareholder approval for the proposed amendments to the Articles of Association and the Trust Agreement.
• Failure to complete the initial business combination, leading to the company's liquidation.
• High redemption rates by public shareholders, which would significantly reduce the capital available in the Trust Account for the business combination.
• Lack of sufficient liquidity in the company's public securities, making it difficult for shareholders to sell their Public Shares in the open market.
• The Trust Account being subject to claims from third parties, potentially reducing the per-share redemption price.
• If the Article Amendment Proposal is not approved and the business combination is not completed by December 6, 2025, the company will be forced to liquidate.
• The company may require additional funds to complete a business combination if redemptions are high, and there is no assurance such funds will be available on acceptable terms or at all.
• If the Trust Agreement Amendment Proposal is not approved, the Sponsor may not agree to fund additional monthly extensions, which would lead to the company's liquidation.

Future Outlook

The company expects to close its business combination with United Hydrogen Group Inc. in early 2026, contingent on shareholder approvals and regulatory clearances. The proposed extension of the business combination deadline to December 6, 2026, is intended to provide sufficient time to complete this transaction.

Management Comments

• "While using the best efforts to complete its business combination with United Hydrogen as soon as practicable, the Board believes that there may not be sufficient time for the Company to complete a business combination before December 6, 2025."
• "The Board believes that in order to be able to consummate the business combination, the Company will need to extend the Termination Date from 24 months from the date of the Company's IPO (namely, December 6, 2025) to as late as 36 months from the date of the Company's IPO (namely, December 6, 2026)."
• "Without the Extension, the Board believes that there is significant risk that the Company might not, despite its best efforts, be able to complete a business combination on or before December 6, 2025."
• "The purpose of the Trust Agreement Amendment Proposal is to provide the Sponsor with an incentive and lessen the Sponsor's burden to fund the fees for each Monthly Extension."
• "The Board expresses no opinion as to whether you should redeem your Public Shares in connection with the Article Amendment Proposal."

Industry Context

This filing is typical for a Special Purpose Acquisition Company (SPAC) nearing its initial business combination deadline. SPACs often seek extensions to finalize mergers, especially complex ones, to avoid liquidation. The reduction in sponsor contribution for extensions is a common incentive mechanism to encourage sponsors to continue supporting the SPAC through the extended period, reflecting the challenges in the current M&A environment for SPACs. The potential for high redemptions is also a prevalent issue in the SPAC market, impacting the capital available for the de-SPAC transaction.

Comparison to Industry Standards

• The need for an extension beyond 24 months is common for SPACs, especially given the increased regulatory scrutiny and market volatility impacting de-SPAC transactions. Many SPACs have struggled to find suitable targets or complete mergers within initial timelines.
• The reduction in the monthly extension fee for the sponsor is a trend observed across the SPAC industry, as sponsors face increasing financial burdens and reduced incentives in a challenging market. This aims to align sponsor interests with public shareholders by making extensions more feasible.
• The redemption price of approximately $11.33 per share, compared to the IPO price of $10.00, is a positive for shareholders who choose to redeem, reflecting interest earned on the trust account. This is a standard feature of SPACs, but the specific value depends on the trust's performance.
• The approval of the United Hydrogen Business Combination on November 6, 2025, suggests progress, but the subsequent need for an extension indicates that closing conditions or regulatory hurdles are taking longer than initially anticipated, a common occurrence in complex cross-border or emerging technology mergers.

Corporate Governance

Related Party Transactions

• The Sponsor (Aimei Investment Ltd), directors, and officers hold 1,725,000 Founder Shares and 332,000 Private Units, which would be worthless if a business combination is not consummated.
• The Sponsor is responsible for depositing additional funds into the Trust Account for monthly extensions, with the proposed amendment reducing this fee.
• The Sponsor, affiliates, officers, and directors may make Working Capital Loans to the company, repayable without interest or convertible into Private Units (up to $1,500,000).
• The company pays the Sponsor $10,000 per month for general and administrative services, with an unpaid balance of $210,000 as of September 30, 2025.
• Insiders are expected to vote in favor of the proposals and may purchase Public Shares to influence the vote.

Stakeholder Impact

• Shareholders: Public shareholders face a decision to redeem their shares for cash (approx. $11.33) if the extension is approved, or remain invested for the potential United Hydrogen merger. If the extension is not approved and no merger occurs, the company liquidates, and they receive a pro-rata distribution. Those who do not redeem will have their investment tied up longer.
• Sponsor (Aimei Investment Ltd): Benefits from the proposed reduction in monthly extension fees, making it less costly to extend the deadline and protect its investment in Founder Shares and Private Units from becoming worthless.
• Management/Directors: Their interests are aligned with completing a business combination to realize value from their Founder Shares and Private Units, which would be lost upon liquidation.
• United Hydrogen Group Inc.: The target company benefits from the extension, as it provides more time for the merger to close.
• Creditors: The company has obligations to provide for claims of creditors in the event of liquidation.

Next Steps

• Hold an Extraordinary General Meeting on November 26, 2025, to vote on the proposals.
• If proposals are approved, implement the amendments to the Articles of Association and Trust Agreement.
• If the Article Amendment Proposal is approved, public shareholders can exercise redemption rights by November 24, 2025.
• Sponsor to deposit Amended Monthly Extension Fees for subsequent monthly extensions until November 6, 2026, if the Trust Agreement Amendment is approved.
• Work towards closing the business combination with United Hydrogen Group Inc. in early 2026.
• If proposals are not approved and the business combination is not completed by December 6, 2025, the company will liquidate.

Key Dates

Recommendation

The filing presents a mixed bag. The company has identified a target (United Hydrogen) and shareholders have already approved the business combination, which is a positive step for a SPAC. The proposed extension and reduced sponsor fees aim to facilitate the completion of this merger, preventing immediate liquidation. However, the need for an extension itself, coupled with the explicit risk of liquidation if the proposals fail, indicates underlying challenges and delays. The potential for significant redemptions could also dilute the capital available for the merger. Given the current share price is very close to the redemption value, investors have a clear option to redeem and exit with minimal loss or even a slight gain. For those who believe in the United Hydrogen merger, holding shares through the extension period carries the risk of further delays or deal failure, but also the potential upside of a successful combination. The recommendation is 'hold' for investors who are comfortable with the extended timeline and the inherent risks of SPACs, as the board is actively working towards completing the merger, and the redemption option provides a floor near the current price. However, a 'sell' could also be justified for risk-averse investors given the uncertainties.

Keywords

SPAC, Business Combination, Extension, Proxy Statement, Shareholder Meeting, Redemption Rights, Trust Account, United Hydrogen, Aimei Health, Corporate Governance, Merger, SEC Filing